Excess Healthcare Costs and Resource Utilisation of Lyme Borreliosis in Germany: A Propensity Score–Matched Cohort Study

Abstract

ABSTRACTAimLyme borreliosis (LB) is the most common tick‐borne disease in Germany; however, data on the economic burden of LB are limited. In this study, we aim to report healthcare costs, healthcare resource utilisation (HCRU) and diagnostic consumption associated with LB by clinical manifestation.MethodUsing specific case definitions, patients with localised disease (erythema migrans [EM]) or disseminated disease (Lyme arthritis [LA], Lyme neuroborreliosis [LNB] and other rarer manifestations [OTH]) were identified from a claims database in 2016 and followed up for 3 years (2016–2019). After propensity score matching, excess costs and HCRU were calculated as the differences between each LB cohort and the matched control cohort.ResultsOn a per‐patient basis, the excess all‐cause healthcare cost was €130 for EM during Quarter 1 of Year 1, and €1539 for LA, €3248 for LNB and €4137 for OTH during Year 1. Only for OTH, additional €1860 was observed in Year 2. No increase in costs was observed in Year 3. When extrapolated to all German patients with statutory health insurance, LB was associated with €64.5 million in excess costs. Although disseminated manifestations only accounted for 7.8% of all LB cases, they were responsible for 66% of overall costs. In addition, LB patients consumed healthcare resources of 1.4 million excess outpatient visits, 13,000 excess hospitalisations, 96,000 ELISAs and 65,000 Western blots.ConclusionThis study shows the substantial economic burden of LB to the German healthcare system.